Physician profile
Yelin Yang
NPI 1225477250
$3,191.85
in general payments reported to CMS, 2019-2025
20 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $79.12 · 2021: $627 · 2022: $576 · 2023: $787 · 2024: $599 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.66 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,011.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $682.75 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $451.40 | 2019-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $291.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $201.06 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $112.51 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $75.36 | 2019-2024 | |
| Glaxosmithkline, LLC. | $52.23 | 2021-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $50.16 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.78 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.60 | 2023-2024 | Jardiance |
| Amarin Pharma, INC. | $33.06 | 2019 | |
| Merck Sharp & Dohme LLC | $29.61 | 2019 | |
| Eisai INC. | $24.06 | 2024 | |
| Exact Sciences Corporation | $22.09 | 2025 | The Cologuard Plus Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $19.74 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.82 | 2022 | |
| Allergan, INC. | $11.86 | 2020 | |
| Dynavax Technologies Corporation | $6.64 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelin Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.